Fig. 2

Drug delivery formulations in vivo are effectively delivered to inflamed colon and do not have a systemic effect. Images were obtained 7 h after oral administration of Cy7-labeled delivery carriers using an in vivo imaging system (IVIS). a Fluorescence of Cy7 measured in the inflamed colon was observed in all drug delivery carrier groups. Arrows indicate strong fluorescence signals at the site of inflammation. b In inflamed small intestine, the AC-L group and EAC-L group were measured for fluorescence of Cy7. c Fluorescence images of Cy7 in a multi-well format obtained from organs (heart, lung, liver, spleen, pancreas, and kidney). d Average radiant efficiency of drug delivery formulations distributed in inflamed intestine in comparison to normal conditions. Data representative of eight independent groups with n = 3 mice/group (Vehicle group), n = 1 mice/group (Vehicle with Cy7 labeled L), n = 1 mice/group (Vehicle with Cy7 labeled AC-L), n = 3 mice/group (Vehicle with Cy7 labeled EAC-L), n = 2 mice/group (DSS colitis with vehicle), n = 2 mice/group (DSS colitis with Cy7 labeled L), n = 2 mice/group (DSS coltis with Cy7 labeled AC-L), n = 2 mice/group (DSS colitis with Cy7 labeled EAC-L. Data are expressed as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Statistical significance was assessed using Student’s t-test (d) and one-way ANOVA followed by Dunnett post-test. Control, treated with vehicle; DSS+Cy7_AC-L, DSS colitis with aminoclay-liposome-coated Cy7; DSS+Cy7_EAC-L, DSS colitis with Eudragit S100-liposome-coated Cy7; DSS+Cy7_L, DSS colitis with liposome-coated Cy7